Lack of Any Relationship Between Circulating Autoantibodies and Interleukin-6 Levels in Egyptian Patients Infected with the Hepatitis C Virus

  • Nasr, Mohamed Y (Molecular Biology department, Genetic Engineering and Biotechnology Research Institute, Sadat City University) ;
  • Deeb, Ammar S Ali (Molecular Biology department, Genetic Engineering and Biotechnology Research Institute, Sadat City University) ;
  • Badra, Gamal (Internal Medicine Department, National Liver Institute, Menoufiya University) ;
  • Sayed, Ibrahim H El (Molecular Biology department, Genetic Engineering and Biotechnology Research Institute, Sadat City University)
  • Published : 2016.11.01


Introduction: Elevated serum interleukin (IL) 6 has been reported in patients infected with the hepatitis C virus (HCV), but it remains debatable whether this influences the production of autoantibodies and the biochemical profile of HCV disease. Therefore, this current study was conducted to evaluate the relationship between IL-6 and circulating autoantibody levels in HCV positive patients. Methods: Levels of IL-6 in serum samples from 102 patients with HCV and 103 normal controls were determined by enzyme linked immunosorbent assay (ELISA). Autoantibodies were detected by immunofluorescence. Results: Levels of IL-6 were significantly higher (p=0.028) in patients infected with (HCV) compared with normal group. Autoantibodies were noted in in 43.1% of the patients; of these, 23.5% featured anti-nuclear antibodies (ANA+), 16.7% anti-smooth muscle antibodies (ASMA+), 7.8% anti-mitochondrial antibodies (AMA+), 17.6% anti-parietal cell antibodies (APCA+), 7.8% anti canalicular antibodies, and 2.9% anti reticulin antibodies (ARA+). No patients were found to be positive for anti-brush border antibodies (ABBA) or anti-ribosomal antibodies. (ARiA). No links with IL-6 levels were apparent. Conclusions: IL-6 levels are increased in patients infected with HCV disease and could influence the production of autoantibodies. However, this study did not provide evidence of a specific relationship between IL6 and circulating autoantibodies in such cases.


  1. Abdel-Rahman Z, Mohammed A, Ahmed H, et al (2005). Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression. World J Gastroenterol, 42, 6624-30.
  2. Barzilai O, Ram M, Shoenfeld Y (2007). Viral infection can induce the production of autoantibodies. Curr Opin Rheumatol, 19, 636-43.
  3. Bortolotti F, Vajro P, Balli F, et al (1996). Non-organ specific autoantibodies in children with chronic hepatitis C. J Hepatol, 25, 614-20.
  4. Bonkovsky HL, Mehta S (2001). Hepatitis C: a review and update. J Am AcadDermatol. J Am Acad Dermatol, 44, 159-82.
  5. Bowcock AM, Kidd JR, Lathrop GM, et al (1988). The human "interferon-beta 2/hepatocyte stimulating factor/interleukin-6" gene: DNA polymorphism studies and localization to chromosome 7p21. Genomics, 3, 8-16.
  6. Campisi L, Barbet G, Ding Y, et al (2016). Apoptosis in response to microbial infection induces autoreactive TH17 cells. Nat Immunol, 17, 1084-92.
  7. Carrion AF, Martin P (2012). Viral hepatitis in the elderly. Am J Gastroenterol, 107, 691-7.
  8. Cassani F, Cataleta M, Valentini P, et al (1997). Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact of the disease profile. J Hepatol, 26, 561-6.
  9. Chihara N, Aranami T, Sato W, et al (2011). Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitisoptica. Proc Natl Acad Sci USA, 108, 3701-6.
  10. Christoffer S, Kristina C, Maria I, et al (2012). High prevalence of autoantibodies to C reactive protein in patients with chronic hepatitis C infection: association with liver fibrosis and portal inflammation. Hum Immuno, 73, 382-8.
  11. Clifford BD, Donahue D, Smith L, et al (1995). High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. J Hepatol, 21, 613-9.
  12. Comanescu C, Bleotu C, Huica I, et al (2015). Non-invasive method for the evaluation of IL-6 and IL-10 levels in patients with chronic hepatitis C. Rom Biotech Lett, 20, 1-6.
  13. Dammacco F, Sansonno D, Piccoli C, et al (2000). The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. Semin Liver Dis, 20, 143-57.
  14. Drygiannakis D, Lionis C, Drygiannakis I, et al (2001). Low prevalence of liver-kidney microsomal autoantibodies of type 1 (LKM1) in hepatitis C seropositive subjects on Crete, Greece. Gastroenterol, 1, 4-16.
  15. Duclos JC, Pateron D, Joannet C, et al (1994). High prevalence of anti-HCV antibodies in patients with Hashimoto's thyroiditis. BMJ, 309, 846-7.
  16. Zusinaite E, Metskula K, Salupere R, et al (2005). Autoantibodies and hepatitis C virus genotypes in chronic hepatitis C patients in Estonia. World J Gastroenterol, 11, 488-91.
  17. Fallahi P, Ferri C, Ferrari SM, et al (2012). Cytokines and HCVrelated disorders. Clin Dev Immunol, 107, 1155-65.
  18. Giannitrapani L, Soresi M, Balasus B, et al (2013). Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. World J Gastroenterol, 19, 2449-55.
  19. Giannitrapani L, Soresi M, Giacalone A, et al (2011). IL-6-174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. OMICS, 15, 183-6.
  20. Gregorio GV, Pensati P, Iorio R, et al (1998). Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection. Clin Exp Immunol, 112, 471-6.
  21. Kammer AR, van der Burg SH, Grabscheid B, et al (1999). Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med, 190, 169-76.
  22. Kim do Y, Han KH. (2012). Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer, 1, 2-14.
  23. Lenzi M, Bellentani S, Saccoccio G, et al (1999). Prevalence of non-organ-specific autoantibodies and chronic liver disease ingeneral population: a nested case-control study of the Dionysoscohort. Gut, 45, 435-41.
  24. Luo JC, Hwang SJ, Li CP, et al (1998). Clinical significance of serum auto-antibodies in Chinese patients with chronic hepatitis C: Negative role of serum viral titre and genotype. J Gastroenterol Hepatol, 13, 475-9.
  25. Malaguarnera M, Di Fazio I, Romeo MA, et al (1997). Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus. J Gastroenterol, 32, 211-5.
  26. Malaguarnera M, Di Fazio, A Laurino A, et al (1997). Serum interleukin 6 concentrations in chronic heaptitis C patients before and after interferon-alpha treatment. Int J Clin Pharmacol Ther Toxicol, 35, 385-8.
  27. Markle JG, Frank DN, Adeli K, et al (2014). Microbiome manipulation modifies sex-specific risk for autoimmunity. Gut Microbes, 5, 485-93.
  28. Martinez F, Abril ER, Earnest DL, Watson RR (1992). Ethanol and cytokine secretion. Alcohol, 9, 455-8.
  29. Marconcin M, Fayad L, Beatriz M, et al (2013). Autoantibody profile in individuals with chronic hepatitis C. Rev Soc Bras Med Trop, 46, 147-53.
  30. McMurray RW, Elbourne K (1997). Hepatitis C virus infection and autoimmunity. Semin Arthritis Rheum, 26, 689-701.
  31. Nakamura RM (1974). Immunopathology-Clinical Laboratory Concepts and Methods, Little, Brown and Co. Boston Edt , 1.
  32. Obermayer-Straub P, Manns MP (2001). Hepatitis C and D, retroviruses and autoimmune manifestations. J Autoimmun,16, 275-85.
  33. Ouyang W, Rutz S, Crellin NK, et al (2011). Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Ann Rev Immunol, 29, 71-109.
  34. Oyanagi Y, Takahashi T, Matsui S, et al (1999). Enhanced expression of interleukin-6 in chronic hepatitis C. Liver, 19, 464-72.
  35. Strassburg CP, Obermayer-Straub P, Manns MP, et al (2000). Autoimmunity in liver diseases. Clin Rev Allergy Immunol, 18, 127-39.
  36. Shihara K, Hirano T (2002). IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev, 13, 357-68.
  37. Spanakis NE, Garinis GA, Alexopoulos EC, et al (2002). Cytokine serum levels in patients with chronic HCV infection. J Clin Lab Anal, 16, 40-6.
  38. Sousa GM, Oliveira RC, Pereira MM, et al (2011). Autoimmunity in hepatitis C virus carriers: involvement of ferritin and prolactin. Autoimmun Rev, 20, 210-3.
  39. Soresi M, Giannitrapani L, D'Antona F, et al (2006). Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol, 12, 2563-8.
  40. Ripley BJ, Goncalves B, Isenberg D, Latchman DS, Rahman A (2005). Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis, 64, 849-53.
  41. Talaat R, Abdel-Aziz A, El-Maadawy E, et al (2015). CD38 and interleukin 6 gene polymorphism in Egyptians with diffuse large B-cell lymphoma (DLBCL). Immunol Invest, 25, 1-14.
  42. Toru E, Hong S, Morshed A, et al (1992). Studies on anti brush border antibodies in sera from patients with liver diseases, and the apparent molecular weights of the target antigens. Seibutsu Butsuri Kagaku, 36, 125-31.
  43. Ueyama M, Nakagawa M, Sakamoto, et al (2011). Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-${\alpha}2b$ plus ribavirin. Antiviral Therapy, 16, 1081-91.
  44. Valentini G, Mantelli A, Persico M, et al (1999). Serological and clinical markers of autoimmune disease in HCVinfected subjects with different disease conditions. Clin Exp Rheumatol, 17, 75-9.